These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17006963)

  • 21. Varicose veins--Who should be referred?
    Onida S; Davies AH; Franklin I
    Phlebology; 2015 Nov; 30(2 Suppl):4-8. PubMed ID: 26556696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiofrequency ablation vs conventional surgery for varicose veins - a comparison of treatment costs in a randomised trial.
    Subramonia S; Lees T
    Eur J Vasc Endovasc Surg; 2010 Jan; 39(1):104-11. PubMed ID: 19879166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elicitation of informed general population health state utility values: a review of the literature.
    McTaggart-Cowan H
    Value Health; 2011 Dec; 14(8):1153-7. PubMed ID: 22152187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The European burden of primary varicose veins.
    Moore HM; Lane TR; Thapar A; Franklin IJ; Davies AH
    Phlebology; 2013 Mar; 28 Suppl 1():141-7. PubMed ID: 23482550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis.
    Ubel PA; Richardson J; Menzel P
    Health Econ; 2000 Mar; 9(2):127-36. PubMed ID: 10721014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QALY-maximisation and public preferences: results from a general population survey.
    Bryan S; Roberts T; Heginbotham C; McCallum A
    Health Econ; 2002 Dec; 11(8):679-93. PubMed ID: 12457369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nothing About Us Without Us? A Comparison of Adolescent and Adult Health-State Values for the Child Health Utility-9D Using Profile Case Best-Worst Scaling.
    Ratcliffe J; Huynh E; Stevens K; Brazier J; Sawyer M; Flynn T
    Health Econ; 2016 Apr; 25(4):486-96. PubMed ID: 25689621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What difference does it make? The calculation of QALY gains from health profiles using patient and general population values.
    McNamee P
    Health Policy; 2007 Dec; 84(2-3):321-31. PubMed ID: 17574293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Quality of life and utility measures: clinical parameters for decision-making in health].
    Campolina AG; Ciconelli RM
    Rev Panam Salud Publica; 2006 Feb; 19(2):128-36. PubMed ID: 16551387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing Increments in Utility of Health: An Individual-based Approach.
    Taylor M; Chilton S; Ronaldson S; Metcalf H; Nielsen JS
    Value Health; 2017 Feb; 20(2):224-229. PubMed ID: 28237199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valuing the Q in QALYs: Does providing patients' ratings affect population values?
    Murphy RP; Boyce CJ; Dolan P; Wood AM
    Health Psychol; 2020 Jan; 39(1):37-45. PubMed ID: 31580129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should patients have a greater role in valuing health states?
    Brazier J; Akehurst R; Brennan A; Dolan P; Claxton K; McCabe C; Sculpher M; Tsuchyia A
    Appl Health Econ Health Policy; 2005; 4(4):201-8. PubMed ID: 16466271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporating societal concerns for fairness in numerical valuations of health programmes.
    Nord E; Pinto JL; Richardson J; Menzel P; Ubel P
    Health Econ; 1999 Feb; 8(1):25-39. PubMed ID: 10082141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the effect of disease adaptation information on general population values for hypothetical health states.
    McTaggart-Cowan H; Tsuchiya A; O'Cathain A; Brazier J
    Soc Sci Med; 2011 Jun; 72(11):1904-12. PubMed ID: 21531491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Varicose veins: diagnosis and management.
    Onida S; Davies AH
    Nurs Times; 2013 Oct 16-22; 109(41):16-7. PubMed ID: 24288936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The VEnous INtervention (VEIN) Project.
    Berridge D; Lees T; Earnshaw JJ
    Phlebology; 2009; 24 Suppl 1():1-2. PubMed ID: 19307436
    [No Abstract]   [Full Text] [Related]  

  • 40. Developing methods that really do value the 'Q' in the QALY.
    Dolan P
    Health Econ Policy Law; 2008 Jan; 3(Pt 1):69-77. PubMed ID: 18634633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.